STOCK TITAN

RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.

RxSight, Inc. director Robert J. Palmisano reported receiving a grant of 37,037 restricted stock units (RSUs) of Common Stock as compensation. Each RSU represents the right to receive one share of RxSight common stock. Following this award, he holds 78,076 shares directly.

The RSUs will fully vest in a single tranche if he continues as an Outside Director through the vesting date. Vesting occurs on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders after that grant date.

Positive

  • None.

Negative

  • None.
Insider PALMISANO ROBERT J
Role null
Type Security Shares Price Value
Grant/Award Common Stock 37,037 $0.00 --
Holdings After Transaction: Common Stock — 78,076 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
RSU grant size 37,037 RSUs Restricted stock units granted to Outside Director on June 17, 2026
Shares after grant 78,076 shares Total Common Stock held directly following the reported transaction
Vesting schedule 100% cliff vest Earlier of one-year after June 17, 2026 or next annual stockholders’ meeting
restricted stock unit ("RSU") financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Outside Director financial
"Subject to the Reporting Person's continuing as an Outside Director through such applicable vesting date"
2021 Equity Incentive Plan financial
"Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PALMISANO ROBERT J

(Last)(First)(Middle)
C/O RXSIGHT, INC.
100 COLUMBIA

(Street)
ALISO VIEJO CALIFORNIA 92656

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RxSight, Inc. [ RXST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/17/2026A37,037(2)A(1)78,076D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
2. Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jim Schindler, as Attorney-in-Fact06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RxSight (RXST) report for Robert J. Palmisano?

RxSight reported that director Robert J. Palmisano received a grant of 37,037 restricted stock units of Common Stock. This is a stock-based compensation award, not an open-market purchase, and increases his directly held position reported to 78,076 shares.

Is the RxSight (RXST) Form 4 transaction a stock purchase or a compensation grant?

The Form 4 shows a compensation grant, not a market purchase. Palmisano received 37,037 restricted stock units at no stated purchase price, classified as a grant or award acquisition under transaction code A and described as a non-derivative equity award.

How do the 37,037 RSUs granted to the RxSight (RXST) director vest?

All 37,037 RSUs vest in a single installment if he remains an Outside Director. Vesting occurs on the earlier of the one-year anniversary of the June 17, 2026 grant date or the date of the next annual stockholders’ meeting after that grant date.

What does each RSU represent in the RxSight (RXST) director award?

Each restricted stock unit represents a contingent right to receive one share of RxSight, Inc. Common Stock. The units convert into shares only upon satisfying vesting conditions tied to continued service as an Outside Director through the specified vesting date.

How many RxSight (RXST) shares does Robert J. Palmisano hold after this Form 4?

After the reported grant, Palmisano is shown holding 78,076 shares of RxSight Common Stock directly. This total reflects his position following the award of 37,037 restricted stock units disclosed in the non-derivative transaction section.

What role does RxSight’s 2021 Equity Incentive Plan play in this Form 4 grant?

The RSU grant is made under RxSight’s 2021 Equity Incentive Plan and requires Palmisano to continue as an Outside Director. The plan defines eligibility, including the Outside Director status that must be maintained through the applicable vesting date for the RSUs to vest.